Revolution Medicines, Inc. (RVMD)
Nasdaq · Healthcare · Biotechnology
$207.68+0.50%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $44.5B
- 52-week range
- $45.80 – $224.31
- 52-week change
- +343.62%
- EPS (trailing)
- −$8.87
- Analyst rating
- 1.3 Strong buy
- Next earnings
- Nov 4, 2026
Fiscal year to Dec 2025
- Revenue
- $0K
- Net income
- −$1.1B
- Diluted EPS
- −$5.95
- Free cash flow
- −$914M
From the company’s annual report on SEC EDGAR.
About Revolution Medicines, Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Headquarters: Redwood City, United States · 883 employees · revmed.com